| Literature DB >> 36051451 |
Vassiliki Michou1, Maria Nikodimopoulou2, Asterios Deligiannis1, Evangelia Kouidi3.
Abstract
BACKGROUND: Physical activity levels are significantly lower in kidney transplant (KT) recipients compared to the general population. The effects of exercise training in KT recipients with diabetes mellitus remain unclear, and so little is known about the role of increased exercise on cardiovascular risk and metabolic profile of KT patients. AIM: To investigate the effects of a 6-mo home-based exercise training program on functional capacity, glucose levels and lipid profile of diabetic KT patients.Entities:
Keywords: Diabetes mellitus; Functional capacity; Glucose control; Lipid profile; Renal transplant recipients; exercise
Year: 2022 PMID: 36051451 PMCID: PMC9331407 DOI: 10.5500/wjt.v12.i7.184
Source DB: PubMed Journal: World J Transplant ISSN: 2220-3230
Figure 1Flow chart diagram of the study design. 1Flowchart of participants was based on recommendations from the Consolidated Standards of Reporting Trials. EX: Exercise; C: Control.
Patients’ baseline demographic and clinical data
|
|
|
|
|
| Sex (male/female) | 8/3 | 8/2 | 0.52 |
| Age (yr) | 52.9 ± 9.5 | 53.0 ± 13.1 | 0.51 |
| Height (cm) | 1.6 ± 0.5 | 1.6 ± 0.0 | 0.34 |
| Weight (kg) | 70.8 ± 12.2 | 72.1 ± 6.7 | 0.77 |
| BMI (kg/m2) | 24.4 ± 2.6 | 25.6 ± 2.0 | 0.23 |
| Place of residence | |||
| Rural area | 27.2% (3/11) | 40.0% (4/10) | 0.69 |
| Urban area | 72.7% (8/11) | 60.0% (6/10) | 0.42 |
| Education | |||
| Primary education | 54.5% (6/11) | 40.0% (4/10) | 0.33 |
| Secondary education | 18.1% (2/11) | 10.0% (1/10) | 0.68 |
| Higher education | 9.0% (1/11) | 20.0% (2/10) | 0.65 |
| No education | 18.1% (2/11) | 30.0% (3/10) | 0.70 |
| Employment status | |||
| Employed | 18.1% (2/11) | 10.0% (1/10) | 0.71 |
| Unemployed | 54.5% (6/11) | 40.0% (4/10) | 0.53 |
| Retired | 27.2% (3/11) | 50.0% (5/10) | 0.38 |
| Smoking | 18.1% (2/11) | 10.0% (1/10) | 0.74 |
| eGFR-CKD-EPI equation (mL/min) | 61.0 ± 7.3 | 59.5 ± 8.2 | 0.53 |
| Stage of diabetic nephropathy | |||
| Stage 3 | 81.8% (9/11) | 90.0% (9/10) | 0.77 |
| Stage 4 | 18.1% (2/11) | 10.0% (1/10) | 0.64 |
| Time after KTx (mo) | 47.4 ± 18.3 | 47.8 ± 18.1 | 0.68 |
| Primary causes of ESKD | |||
| Diabetes mellitus | 54.5% (6/11) | 50.0% (5/10) | 0.64 |
| Hypertension | 27.2% (3/11) | 20.0% (2/10) | 0.56 |
| Polycystic kidney disease | 18.1% (2/11) | 10.0% (1/10) | 0.56 |
| Glomerulonephritis | 9.0% (1/11) | 10.0% (1/10) | 0.72 |
| Nephrosclerosis | 9.0% (1/11) | 0.0% (0/10) | 0.55 |
| Reflux nephropathy | 0.0% (0/11) | 10.0% (1/10) | 0.61 |
| Others | 0.0% (0/11) | 10.0% (1/10) | 0.59 |
| Medication | |||
| Statins | 100.0% (11/11) | 100.0% (10/10) | 0.53 |
| Calcium channel blockers | 36.3% (4/11) | 50.0% (5/10) | 0.23 |
| Oral antidiabetic drugs | 18.1% (2/11) | 30.0% (3/10) | 0.51 |
| Angiotensin II receptor blockers/angiotensin converting enzyme blockers | 54.5% (6/11) | 50.0% (5/10) | 0.66 |
| Slow and/or intermediate acting insulin | 81.9% (9/11) | 70.0% (7/10) | 0.47 |
| Immunosuppression therapy (corticosteroid, tacrolimus, mycophenolate mofetil) | 100.0% (11/11) | 100.0% (10/10) | 0.74 |
| Adherence to medication | 90.9% (10/11) | 100.0% (10/10) | 0.82 |
| Hematocrit (%) | 42.1 ± 4.6 | 39.8 ± 4.5 | 0.63 |
| Hemoglobin (g/dL) | 14.1 ± 1.0 | 13.1 ± 1.6 | 0.16 |
| Na+ (mg/dL) | 139.8 ± 2.5 | 140.3 ± 4.3 | 0.90 |
| K+ (mg/dL) | 4.1 ± 0.3 | 4.3 ± 0.5 | 0.15 |
| Ca2+ (mg/dL) | 10.1 ± 0.5 | 9.7 ± 0.9 | 0.94 |
| P (mg/dL) | 2.9 ± 0.5 | 3.4 ± 0.4 | 0.09 |
| Mg+ (mg/dL) | 1.6 ± 0.1 | 1.6 ± 0.3 | 0.50 |
| Fe+ (mg/dL) | 89.8 ± 23.2 | 87.9 ± 16.6 | 0.54 |
| Urea (mg/dL) | 42.2 ± 8.7 | 48.1 ± 16.7 | 0.90 |
| Creatinine (mg/dL) | 1.1 ± 0.2 | 1.2 ± 0.5 | 0.16 |
| Alkaline phosphatase (mg/dL) | 72.1 ± 27.2 | 62.5 ± 10.4 | 0.17 |
| Uric acid (mg/dL) | 5.7 ± 1.1 | 5.9 ± 1.2 | 0.23 |
| 24-h urine albumin level (mg/dL) | 106.4 ± 25.1 | 115.6 ± 20.9 | 0.25 |
Paired-sample t-test for continuous variables. Significant at the 0.05 level (P < 0.05). BMI: Body mass index; KTx: Kidney transplantation; eGFR: Estimated glomerular filtration rate; ESKD: End-stage kidney disease; CKD-EPI: Chronic kidney disease epidemiology collaboration equation; Na: Sodium; P: Potassium; Ca: Calcium; Mg: Magnesium; P: Phosphorus; Fe: Iron.
Lipid and glucose profile at the beginning and the end of the 6-mo clinical trial
|
|
|
| ||||||
|
|
|
|
|
|
|
|
| |
| FPG (mg/dL) | 120.6 ± 28.9 | 104.8 ± 21.9 | 0.01 | 116.1 ± 33.2 | 115.4 ± 33.9 | 0.38 | 0.47 | < 0.05 |
| TC (mg/dL) | 224.8 ± 30.4 | 224.0 ± 30.1 | 0.11 | 229.7 ± 28.8 | 230.8 ± 27.8 | 0.60 | 0.41 | 0.48 |
| TG (mg/dL) | 164.7 ± 14.8 | 150.8 ± 11.6 | < 0.05 | 165.4 ± 19.0 | 165.2 ± 20.5 | 0.67 | 0.11 | 0.04 |
| HDL (mg/dL) | 51.4 ± 8.8 | 57.2 ± 8.7 | < 0.05 | 51.1 ± 7.9 | 51.3 ± 12.6 | 0.43 | 0.56 | 0.06 |
| LDL (mg/dL) | 119.6 ± 11.4 | 119.4 ± 10.9 | 0.27 | 119.4 ± 17.0 | 119.5 ± 16.4 | 0.33 | 0.78 | 0.45 |
| HbA1c (%) | 6.7 ± 0.4 | 6.6 ± 0.4 | 0.01 | 6.5 ± 1.0 | 6.5 ± 1.1 | 0.25 | 0.20 | 0.36 |
Data are expressed as mean ± SD. P > 0.05: Baseline vs 6 mo follow-up; P > 0.05 and P < 0.05: Exercise vs control group. FPG: Fasting plasma glucose; TC: Total cholesterol; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; HbA1c: Hemoglobin A1c.
Functional capacity and respiratory responses at the beginning and the end of the 6-mo clinical trial
|
|
|
| ||||||
|
|
|
|
|
|
|
|
| |
| (VO2)peak (mL/kg/min) | 22.7 ± 3.3 | 23.8 ± 4.2 | 0.02 | 21.9 ± 4.1 | 21.8 ± 3.2 | 0.34 | 0.43 | 0.01 |
| RERmax | 1.1 ± 0.0 | 1.2 ± 0.1 | 0.53 | 1.1 ± 0.0 | 1.1 ± 0.2 | 0.75 | 0.73 | 0.48 |
| VO2/HRmax | 12.6 ± 3.3 | 13.0 ± 3.0 | 0.23 | 12.7 ± 2.9 | 12.8 ± 2.6 | 0.69 | 0.63 | 0.51 |
| VE/ | 37.2 ± 5.0 | 36.3 ± 2.2 | 0.54 | 37.4 ± 4.8 | 37.3 ± 4.5 | 0.56 | 0.54 | 0.62 |
| VE/V | 33.0 ± 4.4 | 32.4 ± 4.3 | 0.60 | 32.9 ± 4.1 | 33.2 ± 3.8 | 0.33 | 0.38 | 0.43 |
Data are expressed as mean ± SD. P > 0.05: Baseline vs 6 mo follow-up; P > 0.05 and P < 0.05: Exercise vs control group. HR: Heart rate; RER: Respiratory exchange ratio; VO2/HRmax: Ratio between VO2 and maximum heart rate; VE: Pulmonary ventilation; VE/(VO2)max: Ventilatory equivalents for oxygen; VE/V(CO2)max: Ventilatory equivalents for carbon dioxide; (VO2)peak: Maximum oxygen consumption.
Figure 2Linear regression analysis between the peak oxygen uptake and glycated hemoglobin (%) after 6 mo in exercise group (HbA1c: Hemoglobin A1c; (VO2)peak: Maximum oxygen consumption.